NCT02811653 Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
| NCT ID | NCT02811653 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 155 participants |
| Start Date | 2015-12-16 |
| Primary Completion | 2028-12-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 155 participants in total. It began in 2015-12-16 with a primary completion date of 2028-12-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.
Eligibility Criteria
Inclusion Criteria: * Patients * Age between 40 and 85 * French mother tongue * Consulting at the Amiens Memory Resource and Research Centre (CMRR) for: * MCI, according to Albert et al.'s criteria (Albert et al., 2011) * Mild dementia (MMSE\>20) due to AD, according to McKhann's criteria (McKhann et al., 2011). * Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005). * Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011). * Social security coverage * Healthy controls * Healthy age and gender matched volunteers will be recruited into the study from the general population. Exclusion Criteria: * Reading or writing difficulties related to a learning disorder or illiteracy. * A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure): * NYHA stage IV dyspnoea. * respiratory impairment requiring oxygen therapy. * liver impairment. * kidney failure, progressing neoplastic disease, or past or present alcohol abuse. * Past or present neurological disorders other than those having prompted consultation in the Memory Clinic: * stroke. * meningitis or encephalitis. * severe head injury. * sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments). * epilepsy (requiring ongoing treatment), * psychiatric disorders (other than treated depression). * treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state. * Impossibility to perform a neuropsychological evaluation or brain MRI. * Withdrawal from the study at any time, if desired. * Pregnancy * Contra-indication to MRI: * nerve stimulators * cochlear implants * ferromagnetic foreign bodies close to nervous structures in the eye or brain * cerebral shunts * dental appliances * Legal guardianship or incarceration.
Contact & Investigator
Daniela ANDRIUTA, PhD
PRINCIPAL INVESTIGATOR
CHU Amiens
Frequently Asked Questions
Who can join the NCT02811653 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02811653 currently recruiting?
Yes, NCT02811653 is actively recruiting participants. Contact the research team at andriuta.daniela@chu-amiens.fr for enrollment information.
Where is the NCT02811653 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT02811653 clinical trial?
NCT02811653 is sponsored by Centre Hospitalier Universitaire, Amiens. The principal investigator is Daniela ANDRIUTA, PhD at CHU Amiens. The trial plans to enroll 155 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.